What is the appropriate metered‑dose inhaler fluticasone dose for a 7‑year‑old child with asthma who is currently receiving budesonide 200 µg twice daily?

Equivalent Fluticasone MDI Dose for a 7-Year-Old on Budesonide 200 mcg Twice Daily

For a 7-year-old child currently on budesonide 200 mcg twice daily (400 mcg total daily dose), the equivalent fluticasone HFA/MDI dose is 176-352 mcg total daily, administered as 88-176 mcg twice daily.

Dose Conversion Based on EPR-3 Guidelines

The child is receiving budesonide DPI 400 mcg/day total (200 mcg BD), which falls in the medium-dose range for children aged 5-11 years according to NAEPP EPR-3 guidelines 1.

Equivalent Fluticasone Dosing:

• Medium-dose fluticasone HFA/MDI for ages 5-11 years: >176-352 mcg/day 1
• This translates to 88-176 mcg twice daily (using the 110 mcg/puff strength)
• Practical dosing: 1 puff of 110 mcg twice daily = 220 mcg/day (most common medium-dose regimen)

Key Considerations for Switching

Potency differences matter: Fluticasone propionate is approximately twice as potent as budesonide on a microgram-per-microgram basis 2, 3. The EPR-3 dosing tables already account for these potency differences in their comparative dose recommendations 1.

Device delivery is critical:

• The guidelines emphasize that preparations are not interchangeable on a mcg or per-puff basis 1
• For children, MDI with spacer/valved holding chamber is essential to enhance lung deposition and reduce local side effects 1
• Every child given inhaled steroids from an MDI should use a large volume spacer 4

Practical Dosing Algorithm

Starting dose selection:

1. If asthma is well-controlled on budesonide 200 mcg BD → Start fluticasone 110 mcg (1 puff) twice daily
2. If asthma control is suboptimal → Consider fluticasone 110 mcg (2 puffs) twice daily initially
3. Titrate to lowest effective dose once control achieved 1

Available fluticasone HFA/MDI strengths: 44,110,220 mcg/puff 1

Monitoring and Adjustment

The most important determinant of appropriate dosing is clinical response 1. Monitor:

• Daytime and nighttime symptoms
• School absences
• Activity limitation
• Rescue medication use (SABA canisters per month)
• Growth velocity (measure height every 3-6 months)

Titration strategy:

• Assess control after 4-6 weeks (maximum benefit may take this long) 5
• Once control achieved for ≥3 months, step down to lowest dose maintaining control 1
• If inadequate response, verify inhaler technique and adherence before increasing dose 1

Safety Considerations

Growth monitoring is essential: Both budesonide and fluticasone can cause transient growth velocity suppression at medium-to-high doses 1. The clinical significance remains uncertain, but:

• Monitor height at regular intervals
• Use lowest effective dose
• Benefits of asthma control outweigh small, nonprogressive reduction in growth velocity 1

Local side effects prevention:

• Use spacer/valved holding chamber with every dose 1
• Rinse mouth and spit after inhalation 1
• This reduces oral thrush (candidiasis), dysphonia, and systemic absorption

Common Pitfalls to Avoid

1. Don't use unmodified MDI without spacer - most children cannot achieve proper coordination 4
2. Don't assume equal dosing across devices - DPI vs MDI delivery differs significantly 1
3. Don't forget to assess technique - poor technique is a major cause of treatment failure 1, 4
4. Don't overlook adherence - twice-daily dosing requires consistent administration 6